Skip to main contentSkip to navigation
Sirius Investors

MREO Stock: Mereo BioPharma Group plc Stock Price, Analysis & Insights

Get live MREO stock price $0.30, comprehensive Mereo BioPharma Group plc stock analysis, charts, news, and expert forecast. Real-time MREO stock data and investment insights.

0.30
1.54%Today
MREOMereo BioPharma Group plc • NASDAQ Global Market • Healthcare
Market Cap
48.05M
Volume
298.24K
52W High
3.05
52W Low
0.20

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the c...

Company Information

CEO
Denise Vera Scots-Knight
Sector
Healthcare
Industry
Biotechnology
Employees
36

Contact Information

Address
One Cavendish Place
Country
GB

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.28) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Mereo BioPharma Group plc shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Mereo BioPharma Group plc
  • Investors should consider how Mereo BioPharma Group plc fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

48.05M

P/E Ratio (TTM)

-1.50

Beta

0.28

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.